Author: Jean-Claude Muller, 穆卓Executive Editor at BtoBioInnovation firstname.lastname@example.org
SPECIAL REPORT #21.2
Novel Drug Approvals for 2020
According to a report issued by the U.S. FDA’s Center for Drug Evaluation and Research (CDER) the agency has approved 53 new drugs and biological products in 2020. If one adds the two news Emergency Use Authorisations (EUA) for COVID-19 vaccines by Pfizer/BioNTech and Moderna and four CBER approved products, the total U.S. FDA approvals amounts to 59, tying the 2018 record.
Similar to previous years, cancer drugs lead the pack with 19 new approvals.
CDER also approved two new drugs for the treatment of Ebola.
In 2020, 55 biopharmaceutical companies saw one or more of their new drug applications (NDA) being approved by the U.S. agency including 25 biotechnology companies which received their first ever approval. Eli Lilly, Gilead and Roche got 3 approvals each, while Incyte and Regeneron got 2 each.
Earlier today the European Medicines Agency (EMA) has given a green light for Moderna’s COVID vaccine. The European Commission is expected to grant an EUA later today. Moderna’s vaccine is already authorised in the U.S., Canada and Israel.
Paris, January 6, 2021
This document has been prepared by btobioinnovation and is provided to you for information purposes only. The information contained in this document has been obtained from sources that btobioinnovation believes are reliable but btobioinnovation does not warrant that it is accurate or complete. The views presented in this document are those of btobioinnovation’s editor at the time of writing and are subject to change. btobioinnovation has no obligation to update its opinions or the information in this document.